Héctor García-Calderó
Grup de recerca
- Malaltia hepàtica i sistema vascular (LiVas) Laboratory technician
Publicacions destacades
-
Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats
Autors:Referència: LIVER INTERNATIONAL 2020. -
Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension.
Autors:Referència: GASTROENTEROLOGY 2018. -
Mitochondria-targeted antioxidant mitoquinone deactivates human and rat HSC and reduces portal hypertension in cirrhotic rats.
Autors:Referència: LIVER INTERNATIONAL 2017. -
Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation
Autors:Referència: SHOCK 2017. -
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Autors:Referència: JOURNAL OF HEPATOLOGY 2016. -
Simvastatin prevents the aggravation of hepatic microvascular dysfunction caused by endotoxemia in cirrhotic rats
Autors:Referència: HEPATOLOGY 2015. -
Metformin reduces hepatic resistance and portal pressure in cirrhotic rats
Autors:Referència: AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 2015. -
Simvastatin maintains function and viability of steatotic rat livers procured for transplantation
Autors:Referència: JOURNAL OF HEPATOLOGY 2013. -
Simvastatin maintains function and viability of steatotic livers procured for transplantation
Autors:Referència: HEPATOLOGY 2012. -
Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats
Autors:Referència: JOURNAL OF HEPATOLOGY 2011.
